These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 36903645)

  • 41. Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
    Lorenzo-Vizcaya A; Fasano S; Isenberg DA
    Immunotargets Ther; 2020; 9():105-110. PubMed ID: 32582577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Fast and Clean BTK Inhibitor.
    Gabizon R; London N
    J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton's Tyrosine Kinase Inhibitors.
    Koraboina CP; Maddipati VC; Annadurai N; Gurská S; Džubák P; Hajdúch M; Das V; Gundla R
    ChemMedChem; 2024 Jan; 19(1):e202300511. PubMed ID: 37916435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
    Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
    J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
    Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
    Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
    Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.
    Szklener K; Michalski A; Żak K; Piwoński M; Mańdziuk S
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
    Robbins DW; Noviski MA; Tan YS; Konst ZA; Kelly A; Auger P; Brathaban N; Cass R; Chan ML; Cherala G; Clifton MC; Gajewski S; Ingallinera TG; Karr D; Kato D; Ma J; McKinnell J; McIntosh J; Mihalic J; Murphy B; Panga JR; Peng G; Powers J; Perez L; Rountree R; Tenn-McClellan A; Sands AT; Weiss DR; Wu J; Ye J; Guiducci C; Hansen G; Cohen F
    J Med Chem; 2024 Feb; 67(4):2321-2336. PubMed ID: 38300987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.
    Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL
    Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
    Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
    Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
    Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
    Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation.
    Goess C; Harris CM; Murdock S; McCarthy RW; Sampson E; Twomey R; Mathieu S; Mario R; Perham M; Goedken ER; Long AJ
    Mod Rheumatol; 2019 May; 29(3):510-522. PubMed ID: 29862859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.
    Nixon S; Duquette D; Doucette S; Larouche JF
    Curr Oncol; 2023 Apr; 30(4):4222-4245. PubMed ID: 37185435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [
    Skaddan MB; Wooten DW; Wilcox KC; Voorbach MJ; Reuter DR; Jia ZJ; Foster-Duke KD; Hickson JA; Vaidyanathan S; Reed AD; Tovcimak AE; Guo Q; Comley RA; Lee L; Finnema SJ; Mudd SR
    Mol Imaging Biol; 2022 Oct; 24(5):830-841. PubMed ID: 35482146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
    Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
    Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.